Gene therapy killed Jesse Gelsinger in 1999. His death triggered FDA shutdowns and nearly ended the field.
In December 2025, Great Ormond Street and UCL published results for BE-CAR7: 82% of children with previously incurable T-cell leukemia achieved deep remission. Two-thirds remain cancer-free at three years. By early 2026, the FDA had granted Breakthrough Therapy designation to a rival off-the-shelf T-cell therapy, and TIME named researcher Waseem Qasim and first patient Alyssa Tapley among the 100 most influential people in health.
Why it matters
These cures exist, but a price tag above $400,000 and a handful of specialized hospitals decide who gets one.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
64%
Patients disease-free with BE-CAR7
After up to 3 years of follow-up, nearly two-thirds remain in remission without detectable cancer
82%
Deep remission rate
Patients who achieved complete molecular response, enabling stem cell transplant
$400K-$1M
Cost per CAR-T treatment
Pricing barrier limiting accessibility, especially for pediatric patients globally
7
FDA-approved CAR-T therapies
As of mid-2026, covering blood cancers, multiple myeloma, and primary CNS lymphoma
14 years
Emily Whitehead cancer-free
First pediatric CAR-T patient, treated April 2012, remains in complete remission
<25%
Relapsed T-ALL survival before BE-CAR7
Children who relapsed faced dismal odds before the new therapy
Voices
Curated perspectives — historical figures and your fellow readers.
Ever wondered what historical figures would say about today's headlines?
Sign up to generate historical perspectives on this story.
14 events
Latest: March 18th, 2026 · 6 months ago
Showing 8 of 14
JK to step
Tap a bar to jump to that date
Jump to
March 2026
Nature Paper Shows In Vivo T-Cell Engineering Works Without Cell Harvesting
LatestResearch Publication
Azalea Therapeutics published research in Nature demonstrating site-specific CAR gene insertion into T-cells inside living animals, bypassing the need to extract and re-engineer cells outside the body. The result: a potential route to far cheaper, faster therapy.
February 2026
TIME Names Qasim and Tapley to Its 2026 Health Influencer List
Recognition
TIME magazine named Professor Waseem Qasim and patient Alyssa Tapley jointly to TIME100 Health 2026, its list of the 100 most influential people in health, citing their world-first BE-CAR7 clinical trial.
January 2026
FDA Grants Breakthrough Therapy Status to Second Off-the-Shelf T-Cell Cancer Therapy
Regulatory
Wugen's WU-CART-007, a CRISPR-edited allogeneic CAR-T therapy targeting CD7, received FDA Breakthrough Therapy designation for relapsed or refractory T-cell ALL and T-cell lymphoblastic lymphoma. In trial, the therapy achieved a 91% overall response rate and a 72.7% complete remission rate.
December 2025
Base-Edited Therapy Results Published in NEJM
Research Publication
Great Ormond Street/UCL team publishes BE-CAR7 results: 82% deep remission, 64% disease-free at 3 years. Ten patients treated total.
June 2025
FDA Removes CAR-T Safety Restrictions
Regulatory
FDA eliminates Risk Evaluation and Mitigation Strategy requirements for all seven approved CAR-T therapies, easing access barriers.
December 2023
FDA Approves First CRISPR Gene Therapies
Regulatory Milestone
Casgevy and Lyfgenia approved for sickle cell disease. Casgevy is first CRISPR-based therapy approved in U.S. Priced at $2.2M and $3.1M.
May 2022
First Human Receives Base-Edited CAR-T Therapy
World First
Alyssa Tapley receives BE-CAR7 at Great Ormond Street Hospital. First application of base-edited cells in humans. No other options remained.
May 2021
Alyssa Tapley Diagnosed with T-Cell Leukemia
Patient Case
13-year-old from Leicestershire diagnosed with aggressive T-ALL after months of misattributed symptoms. Standard treatments fail.
August 2017
FDA Approves Kymriah: First Gene Therapy for Cancer
Regulatory Milestone
Novartis's CAR-T therapy approved for pediatric B-cell leukemia. First gene therapy approved by FDA for any indication. List price: $475,000.
May 2012
Emily Whitehead Cancer-Free on Seventh Birthday
Patient Outcome
After surviving cytokine storm, Emily wakes from medically induced coma. Scans show complete cancer remission. She's discharged weeks later.
April 2012
Emily Whitehead Becomes First Pediatric CAR-T Patient
Breakthrough
Six-year-old with terminal leukemia receives experimental CAR-T therapy at Children's Hospital of Philadelphia. Carl June's team reprograms her immune cells.
January 2000
FDA Suspends Penn's Gene Therapy Program
Regulatory
FDA shuts down University of Pennsylvania's Institute for Human Gene Therapy after finding protocol violations and undisclosed conflicts of interest.
September 1999
Gelsinger Declared Brain Dead; Gene Therapy Field Collapses
Crisis
Four days after treatment, Gelsinger dies from organ failure. FDA launches investigation; gene therapy trials nationwide halt.
18-year-old with liver disorder receives adenoviral gene therapy at University of Pennsylvania. Within 24 hours, severe immune reaction begins.
Scenarios
1
Base-Edited Therapies Become Standard of Care for Relapsed T-ALL
Likely
Discussed by: Blood Cancer UK, UCL researchers, Great Ormond Street Hospital
BE-CAR7's 64% long-term remission rate triggers expanded clinical trials and accelerated regulatory review. Within three years, base-edited CAR-T becomes first-line treatment for relapsed T-cell leukemia in children. Great Ormond Street Hospital's charity funding extends to 20+ patients, generating data for broader FDA and EMA approval. Manufacturing scales through partnerships with biotech firms, though cost remains $400K+. The therapy's 'off-the-shelf' donor cell approach solves CAR-T's manufacturing bottleneck—no need to harvest each patient's cells and wait weeks. Hospitals without gene therapy centers can order pre-made doses. This accessibility shift transforms outcomes for thousands of children annually who relapse after chemotherapy.
2
Cost Barriers and Manufacturing Delays Stall Widespread Adoption
Possible
Discussed by: Health economics researchers, American Journal of Managed Care, patient advocacy groups
Despite clinical success, BE-CAR7 and similar therapies struggle to scale beyond elite research hospitals. The $400K-$1M price tag limits insurance coverage, especially for experimental base-edited therapies not yet FDA-approved. Manufacturing remains centralized in specialized labs with 2-4 week turnaround times. Low- and middle-income countries lack infrastructure entirely. Meanwhile, pharmaceutical companies hesitate to invest in rare pediatric cancers with small addressable markets. Alyssa Tapley's cure remains an outlier available only through compassionate use and clinical trials. The therapy exists but reaches fewer than 100 patients annually worldwide. Gene therapy becomes a tale of two medicines: transformative for those who access it, irrelevant for everyone else.
3
Long-Term Side Effects Emerge, Triggering New Safety Reviews
Unlikely
Discussed by: FDA oncology division, gene therapy researchers, medical journals analyzing 5-year follow-up data
As the first BE-CAR7 patients approach five years post-treatment, unexpected complications surface. Secondary cancers, autoimmune disorders, or chronic inflammation linked to permanently altered immune cells appear in 10-15% of patients. The Jesse Gelsinger precedent looms—regulators move cautiously. The FDA imposes new long-term monitoring requirements and slows approval timelines for base-edited therapies. Clinical trials expand to include more rigorous safety endpoints. The field doesn't collapse, but enthusiasm tempers. Researchers focus on refining base editing precision to minimize off-target effects. Patients and families face agonizing risk-benefit calculations: accept potential long-term unknowns or choose palliative care for terminal cancer today.
4
Next-Gen In Vivo Editing Eliminates Need for Cell Harvesting
Possible
Discussed by: Beam Therapeutics, precision medicine researchers, Nature Biotechnology
Rather than extracting patients' cells, editing them in a lab, and reinfusing them, scientists develop lipid nanoparticles that deliver base editors directly into patients' bodies. A single injection reprograms immune cells in situ within hours. This in vivo approach, already in early trials for sickle cell disease, extends to cancer by 2027. Cost drops from $400K to $50K. Manufacturing disappears as a bottleneck. Community hospitals can administer treatments without specialized cell therapy labs. Accessibility explodes globally. The CAR-T revolution, initially confined to wealthy nations and elite hospitals, becomes democratized. Childhood leukemia mortality rates plummet worldwide as gene therapy shifts from bespoke intervention to scalable medicine.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
1 of 3
1999-2012
Jesse Gelsinger's Death and the Gene Therapy Dark Ages (1999-2012)
18-year-old Jesse Gelsinger died four days after receiving experimental gene therapy for a liver disorder at the University of Pennsylvania in September 1999. His severe immune reaction to the viral vector triggered organ failure and brain death. Investigations revealed undisclosed prior safety problems and financial conflicts of interest. The FDA suspended Penn's entire gene therapy program. Clinical trials nationwide halted. The field entered a 13-year reputational crisis.
Then
Gene therapy research collapsed; funding dried up; public trust evaporated; regulatory oversight intensified dramatically.
Now
Forced reforms in clinical trial safety, informed consent processes, and conflict-of-interest rules. The tragedy became the cautionary tale that shaped modern gene therapy oversight, ultimately enabling safer therapies like CAR-T.
Why this matters now
Gelsinger's death explains why BE-CAR7's success matters so profoundly—it validates that gene therapy, done right, can cure diseases once considered death sentences. The field's redemption arc hinges on proving tragedies like 1999 were preventable failures, not inherent flaws.
2 of 3
2012-2017
Emily Whitehead's Miracle and the CAR-T Breakthrough (2012-2017)
Six-year-old Emily Whitehead, dying from relapsed leukemia after failed chemotherapy, became the first pediatric patient to receive CAR-T therapy at Children's Hospital of Philadelphia in April 2012. Carl June's team reprogrammed her immune cells to hunt cancer. She nearly died from cytokine storm but survived. On her seventh birthday, scans showed complete remission. She left the hospital cancer-free weeks later and remains so 13 years later. Her case proved CAR-T could cure terminal childhood leukemia.
Led to FDA approval of Kymriah in 2017—the first gene therapy approved for cancer. Established CAR-T as standard treatment for certain blood cancers. Six therapies now approved; over 6,000 patients treated by 2021.
Why this matters now
Emily's story directly preceded Alyssa Tapley's. Both were children with no options left who became first-in-human patients for experimental gene therapies. Emily proved CAR-T worked for B-cell cancers; Alyssa proved base editing could extend it to previously untreatable T-cell cancers.
3 of 3
2020-2023
CRISPR Sickle Cell Approvals: From Nobel Prize to Cure (2020-2023)
CRISPR gene editing won the Nobel Prize in Chemistry in 2020. Three years later, in December 2023, the FDA approved Casgevy—the first CRISPR-based therapy for humans—to treat sickle cell disease. Patients' blood stem cells were edited to produce fetal hemoglobin, eliminating painful vaso-occlusive crises. A second therapy, Lyfgenia, used lentiviral vectors instead of CRISPR but achieved similar results. Both priced at $2.2M-$3.1M per patient.
Established CRISPR as viable therapeutic platform beyond cancer. Opened regulatory pathway for other genetic diseases. Highlighted cost and accessibility as critical barriers—life-changing cures that most patients can't afford or access.
Why this matters now
The sickle cell approvals set the regulatory precedent for base-edited therapies like BE-CAR7. They proved FDA would approve CRISPR-based treatments despite gene editing's controversial history, but also demonstrated that scientific breakthroughs don't automatically translate to widespread patient access.
